Cell Therapy Market, By Clinical-use (Therapeutic Area (Malignancies, Muscoskeletal Therapies, Autoimmune Disorders, Dermatology, and Others), Cell Type (Stem Cell Therapies, BM, Blood, & Umbilical Cord-derived Stem Cells, Adipose Derived Cells, and Others), Non-stem Cell Therapies, and Research-use), By Type (Autologous Therapies and Allogenic Therapies), and By Region - Trends, Analysis and Forecast till 2029

Cell Therapy Market was valued at USD 6.4 Billion in 2024 and is projected to grow at a CAGR of 17.4% to reach USD 31.9 Billion by 2034.

Cell therapy (also known as cellular therapy, cell transplantation, or cytotherapy) is a type of therapy in which viable cells are injected, grafted, or implanted into a patient to achieve a medicinal effect, such as transplanting T-cells capable of fighting cancer cells via cell-mediated immunity during immunotherapy or grafting stem cells to regenerate diseased tissues.

Cell therapy began in the nineteenth century, when scientists experimented with infusing animal material to prevent and treat disease. Although such attempts yielded no positive results, further research discovered in the mid-twentieth century that human cells could be used to help prevent the human body from rejecting transplanted organs, eventually leading to successful bone marrow transplantation, which has become standard treatment for patients with compromised bone marrow due to disease, infection, radiation, or chemotherapy. In recent decades, however, researchers have shown a strong interest in stem cells and cell transplantation as a potential new therapeutic option for a variety of disorders, particularly degenerative and immunogenic maladies.

Drivers of the Cell Therapy Market:  

Rise in Prevalence and Incidence of Chronic Diseases:

• The rising prevalence of chronic illnesses such as cancer, musculoskeletal and neurological disorders, chronic injuries, cardiovascular and gastrointestinal disorders, and cancer fuels the demand for cell therapy treatments.

Growing Need for Potent Treatments:

• During the projected period, the demand for potent treatments to minimize disease burden will drive the expansion of the cell therapy market. Celavie Biosciences' 5-year exploratory study on Parkinson's disease demonstrates this, as do other continuing research and development operations.

Strategic Initiatives by Market Players:

• Leading organizations use a variety of methods, including new launches, acquisitions, approvals, expansions, and alliances, to guarantee that their businesses run smoothly, reduce risks, and enhance long-term sales growth.  

Restrains in the Cell Therapy Market:

High Cost of Cell Therapies:

• The high cost of cell therapies, which can range from tens of thousands to millions of dollars each treatment, is a significant barrier. This reduces patient access and adoption, particularly in poor nations with low healthcare funding.

Severe Regulatory standards:

• Therapy development and commercialization are subject to severe regulatory standards, which can cause product approval delays and increase development costs. Navigating the complex regulatory landscape is tough for many businesses.

Lack of Reimbursement Coverage:

• Public and private payers' reimbursement coverage for cell treatments is severely limited. The high cost of these therapies makes it difficult for healthcare systems to give universal access in the absence of proper reimbursement.

Delays in Clinical Trials and therapies:

• The COVID-19 pandemic has slowed cell therapy clinical trials and therapies. Patient visit restrictions, COVID-19 prioritizing, and supply chain disruptions have all had an influence on cell therapy development and delivery.

 The cell therapy market is segmented based on clinical-use, type, and region.

Based on clinical-use, the global cell therapy market is segmented into therapeutic area, cell type, non-stem cell therapies, and research-use. The therapeutic area clinical-use segment is further divided into malignancies, muscoskeletal therapies, autoimmune disorders, dermatology, and others. The cell type clinical use segment is further bifurcated into stem cell therapies, BM, blood, & umbilical cord-derived stem cells, adipose derived cells, and others. On the basis of type, the target market is segmented into autologous therapies and allogenic therapies. Autologous therapies type segment is dominating the global market, owing to increasing demand for effective drugs for degenerative and cardic disorders.

Regional Insights:

Based on region the cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold the largest share in the global market over the forecast period, owing to strong regulatory framework for promoting cellular therapy development. In addition, presence of a raft of companies and high cost of therapies in the U.S. are promoting the growth of the regional market. The Asia Pacific market is expected to witness the highest growth over the forecast period, owing to rising investments by developers and consumers in educating themselves for advanced medicinal therapies in emerging economies of this region.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study the global cell therapy market is segmented based of type, clinical-use, and region.

Active Pharmaceutical Ingredient Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the cell therapy market involves JCR Pharmaceuticals Co. Ltd., Kolon TissueGene, Inc., MEDIPOST, Osiris Therapeutics, Inc., Stemedica Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Anterogen.Co., Ltd., Fibrocell Science, Inc., Vericel Corporation, and PHARMICELL Co., Ltd. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. For instance, in February 2017, Vericel Corporation conducted first implant of MACI in the U.S. for treatment of symptomatic multiple or single full-thickness cartilage defects of the knee. Further, the company has begun to launch its strategies to increase the number of surgeons employing its products in transplantation procedures.

• JCR Pharmaceuticals Co. Ltd.
• Kolon TissueGene, Inc.
• MediPost
• Osiris Therapeutics, Inc.
• Stemedica Cell Technologies, Inc.
• Cells for Cells
• NuVasive, Inc.
• ANTEROGEN.CO., LTD.
• Fibrocell Science, Inc.
• Vericel Corporation